Obesema 1.7mg Injection
Available Pack Sizes
Free Shipping
Order above $200.00
Worldwide Delivery
8-10 Business Days
24/7 Support
Solve your queries
- 100% Genuine Medicines
- Secure International Logistics
- Secure Payment
- Authentic Pharmaceutical Supplier
How to Order from Medionix Pharma
Add Products
Browse our medicines and add the required products to your cart.
Add Products to Cart
Order Method
Place your order easily through WhatsApp or Email support.
Choose Your Ordering Method
Share Details
Provide your delivery address and contact information.
Share Delivery & Prescription Details
Order Dispatched
Your order is packed securely and shipped worldwide.
Order Confirmation & Dispatch
Obesema 1.7mg Injection
contains Semaglutide 1.7mg per weekly dose in a pre-filled pen, manufactured by Abbott. This is the penultimate dose in the Wegovy-range titration schedule, used as a transitional maintenance dose before reaching the maximum 2.4mg target. At 1.7mg, patients experience significantly enhanced weight loss — typically 10–12% of body weight — while building tolerance for the final dose escalation.
Benefits:
- Substantial weight reduction of 10–12% at this intermediate dose level
- Superior appetite suppression and satiety enhancement versus sub-1mg doses
- Critical step in the semaglutide dose escalation ladder to 2.4mg
- Once-weekly injection with consistent, predictable pharmacokinetics
- Manufactured by Abbott to international pharmaceutical standards
How It Works:
At 1.7mg, semaglutide achieves high-level GLP-1 receptor saturation, producing profound appetite suppression, substantial gastric emptying delay, and near-maximal glucose-dependent insulin secretion. The incremental increase from 1mg produces meaningfully greater weight loss while most patients maintain good tolerability established at lower doses.
Dosage and Administration:
Inject 1.7mg subcutaneously once weekly after at least 4 weeks on the 1mg dose. Administer into the abdomen, thigh, or outer upper arm. Rotate injection sites. After 4 weeks at this dose, advance to 2.4mg as directed by your prescriber.
Side Effects:
Common: nausea, diarrhoea, vomiting, constipation, decreased appetite, abdominal pain. Uncommon: headache, fatigue, elevated resting heart rate. Serious: pancreatitis, gallbladder disease, acute kidney injury from dehydration.
Precautions:
Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. Ensure adequate fluid intake to prevent dehydration. Not recommended in pregnancy. Monitor for mood changes.
Obesema Dosage Comparison Guide
| Strength | Best For | Onset | Duration | Link |
|---|---|---|---|---|
| 0.25mg | Lower strength option | 2–4 wks | Weekly | View → |
| 0.5mg | Standard strength option | 2–4 wks | Weekly | View → |
| 1mg | Popular strength option | 2–4 wks | Weekly | View → |
| 1.7mg | Higher strength option | 2–4 wks | Weekly | Current |
| 2.4mg | Maximum strength variant | 2–4 wks | Weekly | View → |
* Always consult your doctor before changing your dosage. This information is for educational reference only.
Frequently Asked Questions
Q1: What is Obesema 1.7mg used for?
Obesema 1.7mg is an intermediate dose in the weight management titration schedule, used for 4 weeks before advancing to the maximum 2.4mg maintenance dose. It delivers substantial weight loss of 10–12% in most patients.
Q2: Is Obesema 1.7mg equivalent to Wegovy 1.7mg?
Yes. Wegovy's dose escalation schedule includes the same 1.7mg step. Obesema 1.7mg contains semaglutide at the same dose and delivers equivalent clinical outcomes at a fraction of the branded cost.
Q3: What if I cannot tolerate Obesema 2.4mg — can I stay on 1.7mg?
Yes. If gastrointestinal side effects at 2.4mg are not manageable, your prescriber may maintain you at 1.7mg long term. This dose still delivers meaningful and clinically significant weight loss.
Q4: How much additional weight loss does 1.7mg give versus 1mg?
Moving from semaglutide 1mg to 1.7mg typically adds approximately 3–5% additional body weight reduction. The exact benefit varies by individual factors including diet and physical activity.
Q5: Are there any additional monitoring requirements at Obesema 1.7mg?
At higher doses, monitoring for pancreatitis symptoms, gallbladder disease, and dehydration becomes more important. Your prescriber should review blood glucose, renal function, and nutritional adequacy regularly.
Customer Reviews
Dr. Maria Santos
Australia · 3 weeks ago
“Good quality product. Shipping was fast and handled with care. Would recommend for professional hospital procurement.”
Michael K.
USA · 2 months ago
“Fast international shipping and professional packaging. Product was exactly as described. Highly recommend this supplier.”
Dr. James Wilson
USA · 1 week ago
“Excellent product quality. Arrived well-packaged with proper cold chain maintained throughout transit. Will order again.”
Priya Sharma
India · 1 month ago
“Prompt response from the team and smooth ordering process. Medicine arrived in original sealed packaging as expected.”
FirstCare Clinic
Canada · 3 months ago
“Good value for bulk procurement orders. Communication was clear and the shipment arrived within the estimated timeframe.”
Related Products
Disclaimer
The information provided on Medionix Pharma is intended for general informational purposes only. It should not be considered as medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before using any medication or starting any treatment.
Medionix Pharma does not encourage self-medication. Customers are responsible for ensuring that purchases comply with local laws and prescription requirements in their country. If you have any questions or concerns regarding the content on our website, please contact us at sales@medionixpharma.com.